Log In
BCIQ
Print this Print this
 

GZ402668

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionHumanized mAb targeting CD52
Molecular Target CD52
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today